Correction: Silencing of Hsp90 cochaperone AhA1 expression decreases client protein activation and increases cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin(Cancer Res (2008) 68:(1188–96) DOI:10.1158/0008-5472.CAN-07-3268);Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin

Cancer Research

Volumn 68, Issue 4, 2008, Pages 1188-1197

  Holmes, Joanna L ^a   Sharp, Swee Y ^a   Hobbs, Steve ^a   Workman, Paul ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; AHSA1 PROTEIN, HUMAN; BENZOQUINONE DERIVATIVE; CHAPERONE; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; SMALL INTERFERING RNA; TANESPIMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CELL STRAIN HCT116; CELL STRAIN HT29; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BENZOQUINONES; CELL LINE, TUMOR; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HT29 CELLS; HUMANS; LACTAMS, MACROCYCLIC; MOLECULAR CHAPERONES; NEOPLASMS; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 40449089789     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-3577     Document Type: Erratum

References (56)

1. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72. (Pubitemid 41400776)
2. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3-24. (Pubitemid 34462457)
3. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 2003;3:349-58. (Pubitemid 37128321)
4. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17: 361-73. (Pubitemid 30135903)
5. Jakob U, Lilie H, Meyer I, Buchner J. Transient interaction of Hsp90 with early unfolding intermediates of citrate synthase. Implications for heat shock in vivo. J Biol Chem 1995;270:7288-94.
6. Freeman BC, Morimoto RI. The human cytosolic molecular chaperones hsp90, hsp70 (hsc70) and hdj-1 have distinct roles in recognition of a non-native protein and protein refolding. EMBO J 1996;15:2969-79.
7. Whitesell L, Mimnaugh EG, De Costa B, et al. Inhibition of heat shock protein HSP90-60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994;91:8324-8.
8. da Rocha DS, Friedlos F, Light Y, et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17- demethoxygeldanamycin. Cancer Res 2005;65:10686-91.
9. Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005;65:6401-8. (Pubitemid 40994428)
10. Grbovic OM, Basso AD, Sawai A, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A 2006;103:57-62. (Pubitemid 43076104)
11. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000;11:355-60. (Pubitemid 30619563)
12. Bijlmakers MJ, Marsh M. Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56(lck). Mol Biol Cell 2000;11:1585-95. (Pubitemid 30307898)
13. Lavictoire SJ, Parolin DA, Klimowicz AC, et al. Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 2003;278:5292-9. (Pubitemid 36801044)
14. Panaretou B, Siligardi G, Meyer P, et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 2002;10:1307-18. (Pubitemid 36050873)
15. Johnson BD, Schumacher RJ, Ross ED, Toft DO. Hop modulates Hsp70/Hsp90 interactions in protein folding. J Biol Chem 1998;273:3679-86. (Pubitemid 28109795)
16. Roe SM, Ali MM, Meyer P, et al. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 2004;116:87-98. (Pubitemid 38156186)
17. Johnson JL, Beito TG, Krco CJ, Toft DO. Characterization of a novel 23-kilodalton protein of unactive progesterone receptor complexes. Mol Cell Biol 1994;14: 1956-63. (Pubitemid 24074591)
18. Fang Y, Fliss AE, Rao J, Caplan AJ. SBA1 encodes a yeast hsp90 cochaperone that is homologous to vertebrate p23 proteins. Mol Cell Biol 1998;18:3727-34. (Pubitemid 28287894)
19. Mayr C, Richter K, Lilie H, Buchner J. Cpr6 and Cpr7, two closely related Hsp90-associated immunophilins from Saccharomyces cerevisiae, differ in their functional properties. J Biol Chem 2000;275:34140-6.
20. Duina AA, Chang HC, Marsh JA, et al. A cyclophilin function in Hsp90-dependent signal transduction. Science 1996;274:1713-5. (Pubitemid 26414903)
21. Panaretou B, Prodromou C, Roe SM, et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo . EMBO J 1998;17: 4829-36. (Pubitemid 28377183)
22. Pearl LH, Prodromou C. Structure and mechanism of the hsp90 molecular chaperone machinery. Annu Rev Biochem 2006;75:271-94. (Pubitemid 44118034)
23. Richter K, Reinstein J, Buchner J. N-terminal residues regulate the catalytic efficiency of the Hsp90 ATPase cycle. J Biol Chem 2002;277:44905-10. (Pubitemid 36159086)
24. McLaughlin SH, Smith HW, Jackson SE. Stimulation of the weak ATPase activity of human hsp90 by a client protein. J Mol Biol 2002;315:787-98. (Pubitemid 34729326)
25. Obermann WM, Sondermann H, Russo AA, et al. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 1998;143:901-10. (Pubitemid 28547391)
26. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004;206:149-57. (Pubitemid 38317285)
27. Chiosis G. Targeting chaperones in transformed systems-a focus on Hsp90 and cancer. Expert Opin Ther Targets 2006;10:37-50. (Pubitemid 43272410)
28. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007;1113:202-16. (Pubitemid 350015011)
29. Roe SM, Prodromou C, O'Brien R, et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999;42:260-6. (Pubitemid 29069861)
30. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271:22796-801. (Pubitemid 26304727)
31. Sepp-Lorenzino L, Ma Z, Lebwohl DE, et al. Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem 1995;270:16580-7.
32. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61. (Pubitemid 46211321)
33. Pacey S, Banerji U, Judson I, Workman P. Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 2006;172: 331-58.
34. Banerji U, Walton M, Raynaud F, et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005;11: 7023-32. (Pubitemid 41428762)
35. Holford J, Sharp SY, Murrer BA, et al. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998;77:366-73. (Pubitemid 28044038)
36. Hobbs S, Jitrapakdee S, Wallace JC. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1a promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 1998;252:368-72. (Pubitemid 28542893)
37. Maloney A, Clarke PA, Workman P. Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. Curr Cancer Drug Targets 2003;3:331-41. (Pubitemid 37128319)
38. Prodromou C, Roe SM, O'Brien R, et al. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75. (Pubitemid 28009419)
39. Vaughan CK, Gohlke U, Sobott F, et al. Structure of an Hsp90-37-Cdk4 complex. Mol Cell 2006;23:697-707.
40. Lotz GP, Lin H, Harst A, Obermann WM. Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J Biol Chem 2003;278: 17228-35. (Pubitemid 36799604)
41. Meyer P, Prodromou C, Liao C, et al. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J 2004;23: 1402-10.
42. Powers MV, Workman P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 2007; 581:3758-69. (Pubitemid 47081010)
43. Schneider C, Sepp-Lorenzino L, Nimmesgern E, et al. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A 1996;93:14536-41. (Pubitemid 26419002)
44. Harst A, Lin H, Obermann WM. Aha1 competes with Hop, p50 and p23 for binding to the molecular chaperone Hsp90 and contributes to kinase and hormone receptor activation. Biochem J 2005;387: 789-96. (Pubitemid 40685714)
45. Hostein I, Robertson D, DiStefano F, et al. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003-9. (Pubitemid 32720963)
46. Maloney A, Clarke PA, Hansen SN, et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2007;67:3239-53. (Pubitemid 46724862)
47. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004;23:2907-18. (Pubitemid 38638852)
48. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10. (Pubitemid 37187270)
49. Clarke PA, Hostein I, Banerji U, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000;19:4125-33.
50. Liu XD, Liu PC, Santoro N, Thiele DJ. Conservation of a stress response: human heat shock transcription factors functionally substitute for yeast HSF. EMBO J 1997;16:6466-77. (Pubitemid 27483272)
51. Hahn JS, Hu Z, Thiele DJ, Iyer VR. Genome-wide analysis of the biology of stress responses through heat shock transcription factor. Mol Cell Biol 2004;24: 5249-56. (Pubitemid 38738160)
52. Stanhill A, Levin V, Hendel A, et al. Ha-ras(val12) induces HSP70b transcription via the HSE/HSF1 system, but HSP70b expression is suppressed in Ha-ras(val12)-transformed cells. Oncogene 2005;25:1485-95.
53. Dolinski KJ, Cardenas ME, Heitman J. CNS1 encodes an essential p60/Sti1 homolog in Saccharomyces cerevisiae that suppresses cyclophilin 40 mutations and interacts with Hsp90. Mol Cell Biol 1998;18:7344-52. (Pubitemid 28533054)
54. Piper PW, Millson SH, Mollapour M, et al. Sensitivity to Hsp90-targeting drugs can arise with mutation to the Hsp90 chaperone, cochaperones and plasma membrane ATP binding cassette transporters of yeast. Eur J Biochem 2003;270:4689-95. (Pubitemid 37487238)
55. Prodromou C, Siligardi G, O'Brien R, et al. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J 1999; 18:754-62. (Pubitemid 29057260)
56. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003;3: 301-23. (Pubitemid 37128317)